RNA as a potential drug target is currently gaining a lot of interest, but the right technologies are not all in place to successfully pursue them. ZoBio and its partner ETH Zurich have been awarded with a €1.2 million EUREKA Eurostars grant, to establish an automated pipeline enabling…

The androgen receptor (AR) pathway drives most metastatic, castration-resistant prostate cancers (mCRPC). Anti-androgen resistance mechanisms include AR gene amplification, C-terminal ligand-binding domain (LBD) mutations and expression of constitutively-active truncated AR splice variants lacking…